Epothilone B enhances Class i HLA and HLA-A2 surface molecule expression in ovarian cancer cells

Ilenia Pellicciotta, Chia-Ping H. Yang, Gary L. Goldberg, Shohreh Shahabi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: Ovarian cancer is the leading cause of death from gynecologic cancers in the United States. Epothilone B (EpoB), Taxol and vinblastine are anti-neoplastic agents that interfere with microtubules and arrest the cell cycle in the G2/M phase. EpoB is being evaluated in phase III clinical trials, and its analogs are currently being used in the treatment of taxane-resistant metastatic breast cancer. Little is known about the effect of these drugs on the immune response to tumors. Cancer cells evade immune recognition by down-regulating HLA Class I expression, allowing escape from immune surveillance and destruction. Our data illustrates the effect of microtubule-interacting agents on HLA Class I and HLA-A2 expression as well as the modulation of cytokine expression in ovarian cancer cells. Methods: Ovarian cancer cells were treated with different concentrations of drugs. Cell surface expression and mRNA transcription of HLA Class I molecules and HLA-A2 was examined. IFNα, IL1β, IL12 and IL6 mRNA expression was also evaluated upon EpoB treatment. Results: Low-dose EpoB, Taxol and vinblastine greatly increased expression of HLA Class I and HLA-A2 molecules in Hey ovarian cancer cells. EpoB does not modulate HLA expression in drug-resistant ovarian cancer cells. The expression of IFNα, IL1β, IL12 and IL6 is also markedly increased upon EpoB treatment. Conclusions: Nanomolar concentrations of microtubule-interacting agents enhance immune-visibility of ovarian cancer cells by increasing HLA Class I and pro-inflammatory cytokine expression. Immune recognition of tumor cells may be improved.

Original languageEnglish (US)
Pages (from-to)625-631
Number of pages7
JournalGynecologic Oncology
Volume122
Issue number3
DOIs
StatePublished - Sep 2011

Fingerprint

HLA-A2 Antigen
Ovarian Neoplasms
Microtubules
Vinblastine
Interleukin-12
Paclitaxel
Interleukin-6
Neoplasms
Pharmaceutical Preparations
Cytokines
Phase III Clinical Trials
Messenger RNA
epothilone B
G2 Phase
Cell Cycle Checkpoints
Cell Division
Cause of Death
Breast Neoplasms

Keywords

  • Epothilone B
  • Hey cells
  • HLA Class I
  • Ovarian cancer
  • Taxol
  • Vinblastine

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Epothilone B enhances Class i HLA and HLA-A2 surface molecule expression in ovarian cancer cells. / Pellicciotta, Ilenia; Yang, Chia-Ping H.; Goldberg, Gary L.; Shahabi, Shohreh.

In: Gynecologic Oncology, Vol. 122, No. 3, 09.2011, p. 625-631.

Research output: Contribution to journalArticle

Pellicciotta, Ilenia ; Yang, Chia-Ping H. ; Goldberg, Gary L. ; Shahabi, Shohreh. / Epothilone B enhances Class i HLA and HLA-A2 surface molecule expression in ovarian cancer cells. In: Gynecologic Oncology. 2011 ; Vol. 122, No. 3. pp. 625-631.
@article{6d0837ee02b4416fbfea9af33bc49476,
title = "Epothilone B enhances Class i HLA and HLA-A2 surface molecule expression in ovarian cancer cells",
abstract = "Objective: Ovarian cancer is the leading cause of death from gynecologic cancers in the United States. Epothilone B (EpoB), Taxol and vinblastine are anti-neoplastic agents that interfere with microtubules and arrest the cell cycle in the G2/M phase. EpoB is being evaluated in phase III clinical trials, and its analogs are currently being used in the treatment of taxane-resistant metastatic breast cancer. Little is known about the effect of these drugs on the immune response to tumors. Cancer cells evade immune recognition by down-regulating HLA Class I expression, allowing escape from immune surveillance and destruction. Our data illustrates the effect of microtubule-interacting agents on HLA Class I and HLA-A2 expression as well as the modulation of cytokine expression in ovarian cancer cells. Methods: Ovarian cancer cells were treated with different concentrations of drugs. Cell surface expression and mRNA transcription of HLA Class I molecules and HLA-A2 was examined. IFNα, IL1β, IL12 and IL6 mRNA expression was also evaluated upon EpoB treatment. Results: Low-dose EpoB, Taxol and vinblastine greatly increased expression of HLA Class I and HLA-A2 molecules in Hey ovarian cancer cells. EpoB does not modulate HLA expression in drug-resistant ovarian cancer cells. The expression of IFNα, IL1β, IL12 and IL6 is also markedly increased upon EpoB treatment. Conclusions: Nanomolar concentrations of microtubule-interacting agents enhance immune-visibility of ovarian cancer cells by increasing HLA Class I and pro-inflammatory cytokine expression. Immune recognition of tumor cells may be improved.",
keywords = "Epothilone B, Hey cells, HLA Class I, Ovarian cancer, Taxol, Vinblastine",
author = "Ilenia Pellicciotta and Yang, {Chia-Ping H.} and Goldberg, {Gary L.} and Shohreh Shahabi",
year = "2011",
month = "9",
doi = "10.1016/j.ygyno.2011.05.007",
language = "English (US)",
volume = "122",
pages = "625--631",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Epothilone B enhances Class i HLA and HLA-A2 surface molecule expression in ovarian cancer cells

AU - Pellicciotta, Ilenia

AU - Yang, Chia-Ping H.

AU - Goldberg, Gary L.

AU - Shahabi, Shohreh

PY - 2011/9

Y1 - 2011/9

N2 - Objective: Ovarian cancer is the leading cause of death from gynecologic cancers in the United States. Epothilone B (EpoB), Taxol and vinblastine are anti-neoplastic agents that interfere with microtubules and arrest the cell cycle in the G2/M phase. EpoB is being evaluated in phase III clinical trials, and its analogs are currently being used in the treatment of taxane-resistant metastatic breast cancer. Little is known about the effect of these drugs on the immune response to tumors. Cancer cells evade immune recognition by down-regulating HLA Class I expression, allowing escape from immune surveillance and destruction. Our data illustrates the effect of microtubule-interacting agents on HLA Class I and HLA-A2 expression as well as the modulation of cytokine expression in ovarian cancer cells. Methods: Ovarian cancer cells were treated with different concentrations of drugs. Cell surface expression and mRNA transcription of HLA Class I molecules and HLA-A2 was examined. IFNα, IL1β, IL12 and IL6 mRNA expression was also evaluated upon EpoB treatment. Results: Low-dose EpoB, Taxol and vinblastine greatly increased expression of HLA Class I and HLA-A2 molecules in Hey ovarian cancer cells. EpoB does not modulate HLA expression in drug-resistant ovarian cancer cells. The expression of IFNα, IL1β, IL12 and IL6 is also markedly increased upon EpoB treatment. Conclusions: Nanomolar concentrations of microtubule-interacting agents enhance immune-visibility of ovarian cancer cells by increasing HLA Class I and pro-inflammatory cytokine expression. Immune recognition of tumor cells may be improved.

AB - Objective: Ovarian cancer is the leading cause of death from gynecologic cancers in the United States. Epothilone B (EpoB), Taxol and vinblastine are anti-neoplastic agents that interfere with microtubules and arrest the cell cycle in the G2/M phase. EpoB is being evaluated in phase III clinical trials, and its analogs are currently being used in the treatment of taxane-resistant metastatic breast cancer. Little is known about the effect of these drugs on the immune response to tumors. Cancer cells evade immune recognition by down-regulating HLA Class I expression, allowing escape from immune surveillance and destruction. Our data illustrates the effect of microtubule-interacting agents on HLA Class I and HLA-A2 expression as well as the modulation of cytokine expression in ovarian cancer cells. Methods: Ovarian cancer cells were treated with different concentrations of drugs. Cell surface expression and mRNA transcription of HLA Class I molecules and HLA-A2 was examined. IFNα, IL1β, IL12 and IL6 mRNA expression was also evaluated upon EpoB treatment. Results: Low-dose EpoB, Taxol and vinblastine greatly increased expression of HLA Class I and HLA-A2 molecules in Hey ovarian cancer cells. EpoB does not modulate HLA expression in drug-resistant ovarian cancer cells. The expression of IFNα, IL1β, IL12 and IL6 is also markedly increased upon EpoB treatment. Conclusions: Nanomolar concentrations of microtubule-interacting agents enhance immune-visibility of ovarian cancer cells by increasing HLA Class I and pro-inflammatory cytokine expression. Immune recognition of tumor cells may be improved.

KW - Epothilone B

KW - Hey cells

KW - HLA Class I

KW - Ovarian cancer

KW - Taxol

KW - Vinblastine

UR - http://www.scopus.com/inward/record.url?scp=80955179580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80955179580&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2011.05.007

DO - 10.1016/j.ygyno.2011.05.007

M3 - Article

VL - 122

SP - 625

EP - 631

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -